Cloxazolam is indicated for use in the short-term treatment of anxiety disorders, but it has also been used in the treatment of depression, schizophrenia, and neurosis, and as an adjunct in the treatment of intractable epilepsy. Cloxazolam is a long acting benzodiazepine. It is believed that benzodiazepines produce their effects modulating the gamma-aminobutyric acid neurotransmitter (GABA) system in the brain, since this GABA enhancing effect was found in several different biological systems. Cloxazolam acts as a prodrug, with pharmacologically active metabolites, which bind to the GABAa receptor.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Cloxazolam, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.